SRRK - Scholar Rock Holding Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.18
-0.56 (-5.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.74
Open10.44
Bid10.14 x 1000
Ask11.00 x 800
Day's Range10.13 - 10.93
52 Week Range6.95 - 23.35
Volume33,995
Avg. Volume115,188
Market Cap302.126M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateMar 15, 2020 - Mar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswire

    Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020

    Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year and announced R&D priorities for 2020. SRK-015: highly specific inhibitor of latent myostatin activation being developed for the treatment of Spinal Muscular Atrophy (SMA).

  • GlobeNewswire

    Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences

    Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company has earned a $25 million milestone payment from Gilead Sciences, Inc. (GILD) for the successful demonstration of efficacy in preclinical in vivo proof-of-concept studies. This is the most advanced program of the collaboration focused on the discovery and development of potent and selective inhibitors of latent transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. “Achieving this important first milestone at the one year mark of the collaboration is indicative of the progress we are making together towards unlocking the potential of this novel approach to TGFβ inhibition in the treatment of patients suffering from fibrotic diseases,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.

  • GlobeNewswire

    Scholar Rock Added to NASDAQ Biotechnology Index

    Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI), effective prior to market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB).

  • Here is What Hedge Funds Think About Scholar Rock Holding Corporation (SRRK)
    Insider Monkey

    Here is What Hedge Funds Think About Scholar Rock Holding Corporation (SRRK)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • GlobeNewswire

    Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

    Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of SRK-015 for the treatment of patients with spinal muscular atrophy (SMA). The planned preliminary PK/PD analysis, which includes data from 29 patients with SMA across all three cohorts, showed dose-proportional drug exposure and demonstrated target engagement, as evidenced by dose-dependent increases of up to 100-fold in the serum levels of latent myostatin following SRK-015 treatment (2 mg/kg and 20 mg/kg doses).

  • Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates

    Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress

    Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by.

  • Analysts See 2 Falling Knives Bouncing Back
    GuruFocus.com

    Analysts See 2 Falling Knives Bouncing Back

    They have a low financial burden Continue reading...

  • GlobeNewswire

    Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 08, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.

  • Hedge Funds Have Never Been This Bullish On Scholar Rock Holding Corporation (SRRK)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Scholar Rock Holding Corporation (SRRK)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]

  • GlobeNewswire

    Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress

    Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that a poster presentation of preclinical and Phase 1 healthy volunteer data for SRK-015 will be presented at the World Muscle Society Congress being held October 1-5, 2019 in Copenhagen, Denmark. SRK-015 is a highly selective inhibitor of the activation of myostatin, a negative regulator of muscle mass, and is being evaluated in the TOPAZ Phase 2 clinical trial for the treatment of patients with Type 2 and Type 3 spinal muscular atrophy (SMA).

  • Will Scholar Rock Continue to Surge Higher?
    Zacks

    Will Scholar Rock Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Scholar Rock Holding.

  • GlobeNewswire

    Scholar Rock to Present at Upcoming Healthcare Conferences

    CAMBRIDGE, Mass., Sept. 04, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.

  • Is There An Opportunity With Scholar Rock Holding Corporation's (NASDAQ:SRRK) 21% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With Scholar Rock Holding Corporation's (NASDAQ:SRRK) 21% Undervaluation?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Scholar Rock Holding...

  • GlobeNewswire

    Scholar Rock Announces Upcoming Departure of Chief Financial Officer

    Scholar Rock Holding Corporation (SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be leaving the Company to pursue other opportunities. The Company has initiated a search for a new Chief Financial Officer. “Scholar Rock’s Board of Directors, management team, and employees are sincerely grateful to Rhonda for her many contributions to the company and we wish her well in her future endeavors,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.

  • GlobeNewswire

    Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress

    Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endPresented.

  • GlobeNewswire

    Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference

    CAMBRIDGE, Mass., Aug. 07, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.

  • Did Changing Sentiment Drive Scholar Rock Holding's (NASDAQ:SRRK) Share Price Down By 19%?
    Simply Wall St.

    Did Changing Sentiment Drive Scholar Rock Holding's (NASDAQ:SRRK) Share Price Down By 19%?

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

  • Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today
    Motley Fool

    Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today

    Find out why these stocks missed the rally.

  • Why Scholar Rock Is Sinking Today
    Motley Fool

    Why Scholar Rock Is Sinking Today

    The good news? The cause of the drop should be a temporary issue.

  • GlobeNewswire

    Scholar Rock Announces Pricing of Public Offering of Common Stock

    Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Scholar Rock from this offering are expected to be $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.

  • GlobeNewswire

    Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

    CAMBRIDGE, Mass., June 19, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.

  • GlobeNewswire

    Scholar Rock Announces Proposed Public Offering of Common Stock

    Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it intends to offer and sell in an underwritten public offering 3,000,000 shares of its common stock.  In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.  All of the shares are being offered by Scholar Rock.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Scholar Rock intends to use the net proceeds from the offering to fund the SRK-015 program for the treatment of Spinal Muscular Atrophy (SMA), the SRK-181 program for the treatment of cancers that are resistant to checkpoint blockade therapies, preclinical activities for other pipeline programs, as well as for working capital and other general corporate purposes.

  • GlobeNewswire

    Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

    “We are pleased to be presenting the Phase 1 SRK-015 trial results at the upcoming Cure SMA annual conference as these data provide initial safety and mechanistic insights for SRK-015 and support our Phase 2 program,” said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. “The pharmacodynamic results from the Phase 1 trial offer initial proof-of-mechanism for Scholar Rock’s unique therapeutic approach of targeting the latent form of growth factors,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.

  • GlobeNewswire

    Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference

    CAMBRIDGE, Mass., May 28, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.